Despite current treatments, myasthenia gravis (MG) still poses a moderate burden on patients, according to data from a digital study of MG communities around the world. Emotional and/or psychological coexisting illnesses also had a considerable impact on the participants’ quality of life, work, and studies,…
News
The rate of death from myasthenia gravis (MG) generally increases with age, but it peaks among teenage boys and older adults — in both men and women — according to a study from China. Researchers also observed that the rate of death is showing an increasing trend over the…
The single breath count test (SBCT), a noninvasive and inexpensive pulmonary function test, may help evaluate respiratory function and identify when symptoms worsen with myasthenia gravis (MG), a review of several studies has found. A cutoff value of 25 or higher in the SBCT was indicative of normal respiratory…
The use of an inactivated vaccine against SARS-CoV-2, the virus that causes COVID-19, is not linked to an increased risk of symptom worsening among people with myasthenia gravis (MG), according to a small study from China. “COVID-19 vaccination has no long-term impact on MG relapse,” researchers wrote. However, a…
People with myasthenia gravis (MG) who are positive for antibodies against the acetylcholine receptor (AChR) — the most common MG-causing antibodies — tend to have increased activation of part of the immune system called the complement cascade, according to a recent study. However, increased complement activation was not…
Vyvgart (efgartigimod alfa-fcab) is now approved in Israel for the treatment of generalized myasthenia gravis (gMG), according to its developer, Argenx. This is the second new approval for Vyvgart in gMG this year, following a similar positive decision in the U.K. in March. The therapy has…
Repeated treatment with under-the-skin efgartigimod had a consistent effect in easing symptoms of generalized myasthenia gravis (gMG), with no new safety issues identified. That’s according to interim data from the Phase 3 extension study ADAPT-SC+ (NCT04818671), which is…
More generalized myasthenia gravis (gMG) patients who received Ultomiris (ravulizumab) in the Phase 3 CHAMPION MG trial achieved a favorable clinical response to treatment relative to those taking a placebo, according to new trial analyses. The proportion of patients achieving that milestone, according to the Myasthenia Gravis Foundation…
People with generalized myasthenia gravis (gMG) treated with the experimental therapy rozanolixizumab in a clinical trial generally experienced reductions in disease severity scores regardless of disease duration, prior treatments, and initial disease severity, new analyses suggest. Findings were presented by Tuan Vu, MD, of the University of South…
Treatment with Vyvgart (efgartigimod alfa-fcab) over two years was found to safely and effectively ease symptoms of generalized myasthenia gravis (gMG) among participants in an open-label extension study, according to an analysis of new data. “This analysis suggests that long-term efgartigimod [Vyvgart] treatment is well tolerated and…
Recent Posts
- Being a woman affects the way I experience myasthenia gravis
- Neurologists see CAR T-cell potential, but questions remain
- MG quality-of-life measures lack consistency, limiting usefulness
- Thymus changes may play larger role in late-onset myasthenia gravis
- 3 symptoms of myasthenia gravis that are often misunderstood